Clinical trial · Interventional
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
The "Upproach" Approach: A Phase 2 Study Of Upfront Intensity Modulated Proton Beam Therapy (Impt) And Concurrent Chemotherapy For Post-Operative Treatment In Loco-Regionally Advanced Endometrial Cancer
NCT04527900CI-TRIAL-00117223terminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): SOC changed and low enrollment
Summary
Brief summary (as posted)
A phase 2 study with the primary objective of testing treatment compliance of Upfront Intensity Modulated Proton Beam Therapy (IMPT) and Concurrent Chemotherapy (UPPROACH) for Post-operative Treatment in Loco-regionally Advanced Endometrial Cancer is non-inferior to the historic compliance rate of the chemoradiation arm of GOG 258 study
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carboplatin and paclitaxel | Drug | — | UNRESOLVED |
| pelvic IMPT (Intensity Modulated Proton Therapy) | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Concurrent chemoradiation
- description
- Concurrent carboplatin and paclitaxel and IMPT (Intensity Modulated Proton Therapy)
- interventionNames
- Drug: carboplatin and paclitaxel
- Radiation: pelvic IMPT (Intensity Modulated Proton Therapy)
Primary outcomes (1)
- measure
- Number of Participants Who Completed Full 6 Cycles of Chemotherapy Concurrently With IMPT
- timeFrame
- End of study, approximately 4 years
- description
- This will be measured as proportion of patients completing full 6 cycles of chemotherapy concurrently with IMPT
Secondary outcomes (7)
- measure
- Number of Participants With Acute GI and Urinary Toxicity
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Surgery must have included a hysterectomy. Bilateral salpingo-oophorectomy, pelvic lymph node sampling, para-aortic lymph node sampling, and omentectomy are optional 2. Patients will be staged according to FIGO 2009 staging system. Eligibility is defined based on clinical-pathologic features. 3. Patients with endometrioid endometrial cancer with the following: * Stage IA grade 3 with extensive LVSI * Stage IB grade 3 * Stage II * Stage III (A, B, and C) * Stage IVA who are recommended adjuvant whole pelvic RT (+/- lower para-aortic up to renal hilum) and systemic chemotherapy. 4. Patients with clear cell, serous papillary carcinoma, or carcinosarcoma with stages IA-III who are recommended adjuvant whole pelvic RT (+/- lower para-aortic up to renal hilum) and systemic chemotherapy. 5. Patients with a GOG Performance Status of 0, 1, or 2 6. Patients with adequate organ function, reflected by the following parameters: * WBC ≥ 3000/mcl * Absolute neutrophil count (ANC) ≥ 1000/mcl * Platelet count ≥ 100,000/mcl * SGOT, SGPT, and alkaline phosphatase ≤ 2.5 X upper limit of normal (ULN) * Bilirubin ≤ 1.5 X ULN * Creatinine ≤ institutional ULN (if serum creatinine \> ULN, estimated GFR ≥ 45 ml/min) 7. Patients who have signed an approved informed consent and authorization permitting release of personal health information 8. Patients must be 18 years of age or older Exclusion Criteria: 1. Patients with leiomyosarcoma 2. Patients with clinically significant pelvic or para-aortic nodal disease, on post-surgery CT scan, that was not dissected and would require higher boost dose 3. Patients with recurrent endometrial cancer with gross nodal or vaginal disease requiring high dose radiotherapy, or history of prior chemotherapy 4. Patients with a history of prior pelvic/abdominal RT or with history of prior cancer treatment that contraindicates this protocol therapy including history of prior chemotherapy for any other malignancy. 5. Patients with a history of serious co-morbid illness or uncontrolled illnesses that would preclude protocol therapy 6. Patients with an estimated survival of less than three months 7. Patients with FIGO 2009 Stage IVB endometrial cancer 8. Patients with a history of myocardial infarction, unstable angina, or uncontrolled arrhythmia within 3 months from enrollment
References
Publications (0)
Data not yet available
No reference posted for this study.